Astragalus Polysaccharide Powder Veterinary Grade API is a hygroscopic, cream-to-tan botanical polysaccharide powder derived from the root of Astragalus membranaceus var. mongholicus through hot-water extraction at 80–95°C, multi-stage plate-and-frame clarification, ethanol precipitation, and spray drying. The product is released as three model designations—APS-V-50, APS-V-70, and APS-V-85—distinguished by total polysaccharide content, endotoxin load, sulfated ash, moisture ceiling, and aqueous solubility. The material is intended as a formulation input for veterinary oral tablets, hard capsules, water-soluble powders, granules, dry premixes, and aqueous solutions; the APS-V-85 model may be considered for injectable development only after site-specific depyrogenation, sterile filtration, and terminal sterility validation are completed. Each shipment is accompanied by a certificate of analysis listing polysaccharide content by phenol–sulfuric acid, loss on drying, sulfated ash, heavy metals by ICP-MS, endotoxin by Limulus amebocyte lysate, and microbial enumeration. The powder is not sterile and is not depyrogenated by default. Table 1 lists representative release limits.

Why Does the Injectable Route Demand Lower Endotoxin and Bioburden Limits Than Oral Powders?

Parenteral administration bypasses the intestinal barrier, so a veterinary-grade powder destined for injectable formulation is controlled for endotoxin even though the dry powder itself is not a finished injectable. Endotoxin is not removed by conventional 0.22 µm sterilizing-grade filtration, and dry-heat depyrogenation above 170°C may degrade the polysaccharide through browning and viscosity loss. For APS-V-85, the release limit is set at ≤ 0.15 EU/mg; however, the formulator must convert this value to the finished dose limit based on the target species, body weight, and route under the applicable veterinary pharmacopoeia. Aqueous solutions containing 10 g/L APS-V-85 can therefore carry 1 500 EU/L if no upstream endotoxin reduction is applied; this level generally requires depyrogenated water and cleanroom blending because finished parenteral limits are dose-dependent and often lower. For equine or bovine large-volume infusions, the finished solution may require single-digit EU/mL levels, so active pharmaceutical ingredient controls alone are insufficient. Published data for this specific product configuration is limited, so pilot-scale Limulus amebocyte lysate recovery studies are required before release.

Direct Compression Fails Unless Flowability and Moisture Are Controlled Within Narrow Ranges

The as-spray-dried powder shows cohesive flow behavior. Production-scale pot trials on a 100 L bin blender with a 0.5% (w/w) colloidal silicon dioxide addition reduce the Hausner ratio from approximately 1.40 to below 1.25, and the Carr index from 30 to below 20. Without flow-aid blending or dry granulation, a rotary tablet press fitted with a force feeder may still exhibit weight variation above 5% at speeds above 60 rpm. The preferred direct-compression path uses roller compaction followed by dry sieving; slugging is less reproducible because the material compressibility is sensitive to feed moisture. If the incoming water content exceeds 7.0% for APS-V-70, granules may adhere to the die wall and cause picking and sticking on 8 mm standard concave punches.

Wet granulation with 5% (w/w) povidone K30 binder solution in purified water is applied in a top-spray fluid-bed granulator with inlet air temperature between 45°C and 55°C. Higher inlet air temperatures above 70°C can cause surface browning and particle fusion on the distributor plate. The granulated mass is dried to a loss-on-drying value of 3.0–5.0% before compression. On a 16-station rotary press, compression forces of 12–22 kN are typical for 10–30% (w/w) polysaccharide tablets with a final hardness of 80–120 N; fracture and capping may occur at lower moisture content below 2.5%. Tablets containing more than 30% polysaccharide commonly require 5% croscarmellose sodium and 5% microcrystalline cellulose to keep disintegration time within acceptable veterinary monograph limits. For hard capsules, a tamping-pin encapsulation line is operated with low pin compression and a powder bed height below 50 mm to prevent densification and plugging in the dosator. The powder should be stored in sealed foil-lined drums at 15–25°C; open handling is not recommended above 60% relative humidity because moisture uptake can reach 2–4% within 30 min.

When the Powder Is Dispersed Into Saline or Phosphate Buffers, High Shear Can Reduce Filter Flux

In aqueous solution manufacture, the dispersion step is preferably conducted in a jacketed stainless-steel vessel with a slow-speed impeller. Addition under high shear above 3,000 rpm can entrain air and generate viscoelastic agglomerates that blind 0.45 µm polyethersulfone cartridge filters. A production-scale batch of 500 L is often filtered through a 1.0 µm prefilter followed by a 0.45 µm final filter; the inline differential pressure should remain below 0.8 bar to avoid gel-layer compaction. If the solution is intended for downstream sterilizing filtration, the temperature should be kept at 20–25°C because chilled polysaccharide solutions may increase viscosity and reduce flux. The pH is maintained between 5.0 and 7.5 with phosphate or citrate buffers; prolonged exposure below pH 3.0 can hydrolyze glycosidic bonds and shift the molecular weight distribution. Solutions should be filtered within 4 h of preparation because polysaccharide solutions are growth-promoting media and may support bioburden increase during holding.

For dry premix and oral powder applications, the powder is blended into a carrier such as dextrose monohydrate or lactose monohydrate in a double-cone or ribbon blender. Metering accuracy is limited by the cohesiveness of the spray-dried powder; a 1,000 kg production ribbon blender fitted with baffles and operated at 70–80% capacity typically achieves a coefficient of variation below 5% for a 1% active premix after 10 min of blending. Over-blending beyond 20 min may increase fines segregation and should be avoided. For water-soluble oral powders, the addition of 1–3% sodium carbonate or citrate is used to adjust reconstitution pH and reduce stringy residue when the powder is mixed with hard well water. The final dry product should be protected from moisture; bulk packaging in aluminum-lined bags inside fiber drums is preferred.

Molecular Weight Distribution and Monosaccharide Fingerprint as Release Criteria

Unlike simple dextrins or maltodextrins, the veterinary-grade API is characterized by high-performance size-exclusion chromatography with refractive index detection against dextran molecular weight standards. Reported production lots show a broad peak between 10 kDa and 500 kDa, although the exact profile varies with root harvest season and precipitation conditions. The monosaccharide fingerprint is typically determined by acid hydrolysis followed by high-performance anion-exchange chromatography with pulsed amperometric detection; glucose, galactose, arabinose, and rhamnose are the major reported residues. This fingerprint allows the buyer to distinguish Astragalus polysaccharide from other botanical polysaccharides or from adulteration with starch hydrolysates, which would show a narrow molecular weight distribution and a glucose-dominated profile. Because no harmonized pharmacopeial monograph exists for this botanical polysaccharide, the responsible manufacturer should qualify the HPSEC-RI method and set lot-release acceptance ranges based on production-scale batches.

What Separates the Veterinary-Grade API from Feed-Grade Extracts and Non-Veterinary Bulk Polysaccharides?

The principal difference is release documentation and contaminant control. Feed-grade extracts are frequently sold on extract ratio or crude polysaccharide content without a validated phenol–sulfuric acid total carbohydrate release limit, and may contain higher levels of sulfated ash, heavy metals, and microbial load. In comparison, APS-V-70 and APS-V-85 are controlled for endotoxin, heavy metals by ICP-MS, and microbial enumeration according to USP 61, USP 62, and USP 85. A second difference is solubility performance: the refined grades show lower insoluble matter and can be filtered through 0.45 µm membranes under moderate pressure, whereas feed-grade powders often produce sediment and rapid filter blinding. A third difference is particle size consistency; the API grades are milled or spray-dried to controlled D90 values, allowing reproducible metering into premix and capsule lines. The product is not intended for use as a direct feed additive without formulation-level dilution and documentation because final label claims and target species tolerances must be established by the finished product registrant under the applicable veterinary medicinal framework.

Stability testing under ICH Q1A(R2) conditions at 25°C ± 2°C/60% RH ± 5% and 40°C ± 2°C/75% RH ± 5% is recommended for finished formulations; published data for the bulk veterinary-grade powder is limited, so a 24-month retest interval is assigned only after real-time data from three consecutive production lots. The powder is incompatible with strong oxidizing agents and with high-valent metal salts such as ferric chloride in solution, which can induce polyelectrolyte complexation and precipitation. It should not be autoclaved as a dry powder, and aqueous solutions exposed to terminal steam sterilization must be checked for viscosity loss, color change, and polysaccharide content by phenol–sulfuric acid. Avoid co-milling with strong acids or acid-releasing buffers because localized low pH may reduce molecular weight and increase reducing sugar values.